Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience.
Saved in:
| Title: | Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience. |
|---|---|
| Authors: | Ebert, Niklas1 (AUTHOR), Rosar, Florian1 (AUTHOR), Burgard, Caroline1 (AUTHOR), Bartholomä, Mark1 (AUTHOR), Maus, Stephan1 (AUTHOR), Hein, Connor1 (AUTHOR), Blickle, Arne1 (AUTHOR), Ezziddin, Samer1 (AUTHOR), Khreish, Fadi1,2 (AUTHOR) fadi.khreish@klinikum-fulda.de |
| Source: | EJNMMI Research. 3/16/2026, Vol. 16 Issue 1, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2191219X |
|---|---|
| DOI: | 10.1186/s13550-026-01408-w |
